Acta Scientific Ophthalmology (ISSN: 2582-3191)

Case Report Volume 4 Issue 10

Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 ROP

Sophia El Hamichi1*, Khushi Saigal1, Estephania Feria Anzaldo1,2, Aaron Gold1, Audina M Berrocal2 and Timothy G Murray1

1Murray Ocular Oncology and Retina, Miami, FL, USA
2Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA

*Corresponding Author: Sophia El Hamichi, Murray Ocular Oncology and Retina, Miami, FL, USA.

Received: July 28, 2021; Published: September 16, 2021


Purpose: This case describes a unique case of an infant referred with stage 4A retinopathy of prematurity (ROP) and plus disease that was successfully controlled with intravitreal injections of bevacizumab.

Methods: Case report.

Results: A 23 months-old-age female born at 23 weeks gestational age with a birth weight of 453 grams and retinopathy of prematurity (ROP) Stage 4A in 360 degrees and plus disease in both eyes treated in another institution with laser, complicated with two cardiac arrests during the procedure.

The patient was referred and treated at 31 weeks with repeated intravitreal bevacizumab injection in both eyes secondary to a progressive ROP.

Treatment with multiple anti-VEGF therapy as monotherapy led to resolution of a retinal detachment (RD) and full vascularization of the retina in both eyes

Conclusion: To the best of the authors’ knowledge, this is the first description of a patient with stage 4A ROP treated solely with anti-VEGF after failed laser treatment that led to complete resolution of an RD without surgical intervention.

Keywords: Retinopathy of Prematurity; Stage 4A; Plus Disease; Laser; Cardiac Arrest; Intravitreal Injection; Anti VEGF


  1. Hellström A., et al. “Retinopathy of prematurity”. Lancet9902 (2013): 1445-1457.
  2. Good WV., et al. “The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study”. Pediatrics1 (2005): 15-23.
  3. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group”. Archives of Ophthalmology2 (1990): 195-204.
  4. Mintz-Hittner HA., et al. “BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity”. The New England Journal of Medicine7 (2011): 603-615.
  5. Good WV and Hardy RJ. “The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP)”. Ophthalmology6 (2001): 1013-1014.
  6. Walter M- Fierson. “Screening examination of premature infants for retinopathy of prematurity”. American Academy of Pediatrics6 (2018): e20183061.
  7. Wang SD and Zhang GM. “Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis”. International Journal of Ophthalmology5 (2020): 806-815.
  8. Ells AL., et al. “Posterior to the ridge laser treatment for severe stage 3 retinopathy of prematurity”. Eye 27 (2013): 525-530.
  9. Narnaware SH and Bawankule PK. “Role of LASERS in stage 4A retinopathy of prematurity (ROP)”. Lasers in Medical Science (2020).
  10. Laser therapy for retinopathy of prematurity. Laser ROP Study Group”. Archives of Ophthalmology2 (1994): 154-156.
  11. Wu WC., et al. “Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan”. Ophthalmology1 (2011): 176-183.
  12. Sukgen EA and Koçluk Y. “Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab”. Graefe's Archive for Clinical and Experimental Ophthalmology2 (2017): 263-269.
  13. Lakhanpal RR., et al. “Anatomic success rate after 3-port lens-sparing vitrectomy in stage 4A or 4B retinopathy of prematurity”. Ophthalmology9 (2005): 1569-1573.
  14. Yokoi T., et al. “Evaluation of scleral buckling for stage 4A retinopathy of prematurity by fluorescein angiography”. The American Journal of Ophthalmology4 (2009): 544-550.
  15. Hinz BJ., et al. “Scleral buckling surgery for active stage 4A retinopathy of prematurity”. Ophthalmology10 (1998): 1827-1830.
  16. Cheng HC., et al. “Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity”. Retina4 (2015): 660-666.
  17. Honda S., et al. “Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity”. Graefe's Archive for Clinical and Experimental Ophthalmology7 (2008): 1061-1063.
  18. Kusaka S., et al. “Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study”. British Journal of Ophthalmology 11 (2008): 1450-1455.
  19. Quiroz-Mercado H., et al. “Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity [published correction appears in”. Retina 1 (2009): 127.


Citation: Sophia El Hamichi., et al. “Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 ROP".Acta Scientific Ophthalmology 4.10 (2021): 14-18.


Copyright: © 2021 Sophia El Hamichi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US